Matt Franz : Zealous For Knowledge

Update On Inotek Pharmaceuticals

As I “went to press” the other day on Inotek, news broke that Inotek signed a merger agreement with Rocket Pharmaceuticals. It’s an all stock deal where Inotek will issue shares to Rocket. Current Rocket shareholders will end up with 81% of the combined company and the rest will go to Inotek shareholders. There will be a final adjustment on the closing date, expected in early 2018, to reflect the amount of cash Inotek has on its balance sheet.

Rocket is a development stage company focused on gene therapy. At first glance this seems like a good deal for them. They have raised capital at a $275 million valuation (Inotek’s NAV, $52.461 million, divided by 19%) and will now be listed on the Nasdaq.

Here is the full press release that you can read in full and here is a link to my prior analysis of Inotek.

This is not a recommendation to buy or sell any stock mentioned. I do not own shares of any stock mentioned. Do your own research: you are accountable for your own returns. Please read my full disclosure.

3 responses to “Update On Inotek Pharmaceuticals”

  1. magnet says:

    Thіs is really interesting, You’re a very skilled blogger.
    I’ve joined your feeԁ and look forward to seeking more of your great post.

    Also, I hɑѵе sharеd your website in my social networks!

  2. I see your website doesn’t rank high in google,
    but your articles can get into top 10. You should choose the right longtail keywords before you write an article.
    How to find super easy longtail keywords? Search in google for: Fasrixo’s tools

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe: rss | email